Mette S. van Ramshorst

Author

The Netherlands Cancer Institute

Also Known As

M. S. van Ramshorst, M.S. van Ramshorst, Mette S van Ramshorst, Mette S. Van Ramshorst, Mette S. van Ramshorst

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Reinier de Graaf Hospital Radboud University Nijmegen Ziekenhuis Groep Twente Isala

About

Mette S. van Ramshorst is an author at The Netherlands Cancer Institute specializing in medicine, breast cancer, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	746
2	Pathology	4	4	214
3	Pharmacology	3	3	459
4	Health Sciences	2	2	71
5	Neurology	1	1	14

Mette S. van Ramshorst

Publications

965

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven, The Lancet Oncology Breast OncologyOncologyDual Her2 BlockadePharmacologyBreast Cancer	2018	413
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven, JAMA Oncology	2021	130
Adjuvant chemotherapy in small node-negative triple-negative breast cancer Tessa G. Steenbruggen, Erik van Werkhoven, Mette S. van Ramshorst, European Journal of Cancer Breast OncologyMedicineAdjuvant ChemotherapyPathologyBreast Cancer	2020	117
MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy Mette S. van Ramshorst, Claudette E. Loo, Emilie J. Groen, Breast Cancer Research and Treatment Breast OncologyRadiologyPathologic Complete ResponseMedicinePathology	2017	43
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study Mette S. van Ramshorst, Erik van Werkhoven, Aafke H. Honkoop, The Breast	2016	38
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst, The Lancet Oncology Neoadjuvant Chemotherapy DurationBreast OncologyMedical ImagingMedicineMri-guided Optimisation	2024	36
Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial. Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven, Journal of Clinical Oncology Breast OncologyOncologyHealth SciencesMedicineMetronomic Therapy	2020	35
The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer Mette S. van Ramshorst, Margriet van der Heiden‐van der Loo, Gwen Dackus, Breast Cancer Research and Treatment Breast OncologyMedicinePathologyBreast CancerCancer Treatment	2016	34
Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study Mette S. van Ramshorst, Erik van Werkhoven, Ingrid A.M. Mandjes, European Journal of Cancer Breast OncologyOncologyWeekly PaclitaxelBreast CancerNeo-adjuvant Treatment	2017	23
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore Tessa G. Steenbruggen, Maartje van Seijen, L. Janssen, Clinical Cancer Research	2019	21

Page 1